glp-1 microdosing for weight loss medications has become a growing topic online. Some people hope a lower dose will reduce side effects, lower costs or quiet food noise without major loss. But lower dose Is It Safe to Microdose

Boosting Cardiovascular Health Maintaining your NAD+ levels can help with numerous health concerns

High-dose cisplatin induces significant renal and hepatic injury

A growing number of employers are drawing a hard line: GLP-1 coverage remains in place, but only for a formal Type 2 diabetes diagnosis

The following is a review of the preclinical and clinical studies examining the role of GLP-1R agonists on the vascular endothelium and HFpEF: Data from preclinical studies In a study on non-diabetic mice models with arterial hypertension (simulating preconditions for HFpEF), Liraglutide treatment improved blood pressure and cardiac hypertrophy in angiotensin II-induced arterial hypertension independent of glucose/insulin modulation leading to the reversal of cardiac hypertrophy